Risk of cardiovascular disorders in psoriasis patients: Current and future

American Journal of Clinical Dermatology

Volumn 14, Issue 1, 2013, Pages 1-7

  Tablazon, Ingrid L D ^a   Al Dabagh, Amir ^a   Davis, Scott A ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; APILIMOD; BRIAKINUMAB; BRODALUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 17; IXEKIZUMAB; METHOTREXATE; PSORALEN; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; VITAMIN D;

ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CYTOKINE RELEASE; DEPRESSION; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; EXERCISE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KERATINOCYTE; METABOLIC SYNDROME X; PATIENT CARE; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PRIORITY JOURNAL; PSORIASIS; PUVA; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING CESSATION; SOCIAL INTERACTION; SYSTEMATIC REVIEW; T LYMPHOCYTE; TH17 CELL; WAIST CIRCUMFERENCE;

ALCOHOL DRINKING; CARDIOVASCULAR DISEASES; HUMANS; LIFE STYLE; MASS SCREENING; METABOLIC SYNDROME X; PATIENT CARE; PRACTICE GUIDELINES AS TOPIC; PSORIASIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SMOKING CESSATION;

EID: 84873825998     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-012-0005-5     Document Type: Article

References (57)

1. Fernandez-Torres R, Pita-Fernandez S, Fonseca E. Psoriasis and cardiovascular risk: assessment by different cardiovascular risk scores. J Eur Acad Dermatol Venereol. 2012. [Epub ahead of print].
2. Mercuri SR, Naldi L. Potential role of ustekinumab in the treatment of chronic plaque psoriasis. Biologics. 2010;4:119-29.
3. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. Dermatol Ther. 2010;23(2):114-8.
4. Horn EJ, Fox KM, Patel V, et al. Are patients with psoriasis undertreated? Results of National psoriasis foundation survey. J Am Acad Dermatol. 2007;57(6):957-62.
5. Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of the metabolic syndrome in psoriasis: results from the National health and nutrition examination survey, 2003-2006. Arch Dermatol. 2011;147(4):419-24.
6. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145(6):700-3.
7. Gisondi P, Farina S, Giordano MV, et al. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol. 2010;106(12):1754-7.
8. Jensen P, Thyssen JP, Zachariae C, et al. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int J Dermatol. 2012. [Epub ahead of print].
9. Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J. 2012;33(16):2054-64.
10. Kremers HM, McEvoy MT, Dann FJ, et al. Heart disease in psoriasis. J Am Acad Dermatol. 2007;57(2):347-54.
11. Zhang K, Li X, Yin G, et al. Functional characterization of T cells differentiated in vitro from bone marrow-derived CD34 cells of psoriatic patients with family history. Exp Dermatol. 2010;19(8):e128-35.
12. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med. 2008;263(5):517-27.
13. Miossec P. IL-17 and Th17 cells in human inflammatory diseases. Microbes Infect. 2009;11(5):625-30.
14. Eid RE, Rao DA, Zhou J, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009;119(10):1424-32.
15. Cheng X, Yu X, Ding YJ, et al. The Th17/Treg imbalance in patients with acute coronary syndrome. Clin Immunol. 2008;127(1):89-97.
16. Kagen MH, McCormick TS, Cooper KD. Regulatory T cells in psoriasis. Ernst Schering Res Found Workshop. 2006;56:193-209.
17. Mor A, Luboshits G, Planer D, et al. Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J. 2006;27(21):2530-7.
18. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509.
19. Tonel G, Conrad C. Interplay between keratinocytes and immune cells: recent insights into psoriasis pathogenesis. Int J Biochem Cell Biol. 2009;41(5):963-8.
20. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta. 2008;394(1-2):7-21.
21. Csiszar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFalpha may promote coronary artery disease. Med Hypotheses. 2004;63(4):696-8.
22. Armstrong AW, Voyles SV, Armstrong EJ, et al. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20(7):544-9.
23. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005;26(20):2083-92.
24. McDonald I, Connolly M, Tobin AM. A review of psoriasis, a known risk factor for cardiovascular disease and its impact on folate and homocysteine metabolism. J Nutr Metab. 2012. [Epub ahead of print].
25. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease: the European concerted action project. JAMA. 1997;277(22):1775-81.
26. Ahdout J, Kotlerman J, Elashoff D, et al. Modifiable lifestyle factors associated with metabolic syndrome in patients with psoriasis. Clin Exp Dermatol. 2012;37(5):477-83.
27. Gans KM, Risica PM, Wylie-Rosett J, et al. Development and evaluation of the nutrition component of the rapid eating and activity assessment for patients (REAP): a new tool for primary care providers. J Nutr Educ Behav. 2006;38(5):286-92.
28. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin. 2005;23(4):681-94.
29. Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031-42.
30. Gelfand JM, Mehta NN, Langan SM. Psoriasis and cardiovascular risk: strength in numbers, part II. J Invest Dermatol. 2011;131(5):1007-10.
31. Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262-7.
32. Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066-73.
33. Boehncke WH, Boehncke S, Schon MP. Managing comorbid disease in patients with psoriasis. BMJ. 2010;340:b5666. doi: 10.1136/bmj.b5666.:b5666.
34. Waisman A. To be 17 again: anti-interleukin-17 treatment for psoriasis. N Engl J Med. 2012;366(13):1251-2.
35. Cingoz O. Ustekinumab. MAbs. 2009;1(3):216-21.
36. Nair RP, Ruether A, Stuart PE, et al. Polymorphisms of the IL12B and IL23R genes are associated with psoriasis. J Invest Dermatol. 2008;128(7):1653-61.
37. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371(9625):1665-74.
38. Ionescu MA, Lipozencic J. Could anti IL12/23 therapy replace anti-TNF biologics? Acta Dermatovenerol Croat. 2009;17(3):166-9.
39. Shaker OG, Moustafa W, Essmat S, et al. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem. 2006;39(2):119-25.
40. Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Wolff K, et al., editors. Fitzpatrick's dermatology in general medicine. New York: McGraw Hill; 2008. p. 169-74.
41. Reddy M, Davis C, Wong J, et al. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cell Immunol. 2007;247(1):1-11.
42. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med. 2007;356(6):580-92.
43. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371(9625):1675-84.
44. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol. 2008;144(2):200-7.
45. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol. 2011;164(4):862-72.
46. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011;306(8):864-71.
47. Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci. 2011;63(3):154-63.
48. Reich K, Papp KA, Griffiths CE, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300-12.
49. Tzellos T, Kyrgidis A, Zouboulis CC. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol. 2012. [Epub ahead of print].
50. Roark CL, Simonian PL, Fontenot AP, et al. Gammadelta T cells: an important source of IL-17. Curr Opin Immunol. 2008;20(3):353-7.
51. Reich K. Anti-interleukin-17 monoclonal antibody ixekizumab in psoriasis (letter). N Engl J Med. 2012;367(3):274.
52. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17- receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9.
53. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-9.
54. Feldman SR, Ravis S, Moran WP, et al. Patients seen in a dermatology clinic have unmet preventive health care needs. J Am Acad Dermatol. 2001;44(4):706-9.
55. Fenerty SD, West C, Davis SA, et al. The effect of reminder systems on patients' adherence to treatment. Patient Prefer Adherence. 2012;6:127-35.
56. Feldman SR, Horn EJ, Balkrishnan R, et al. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol. 2008;59(6):1009-16.
57. Martin SL, McGoey ST, Bebo Jr BF, et al. Patients' educational needs about topical treatments for psoriasis. J Am Acad Dermatol. 2012. [Epub ahead of print].